Larimar Therapeutics, Inc. — Filing identity and period
Important identity discrepancy: The supplied filing is Zafgen, Inc.’s Form 10-Q for the quarter ended June 30, 2019, filed August 8, 2019. It is not identified in the filing as Larimar Therapeutics, Inc. Investors should verify the issuer before relying on this summary.
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases. It had no product revenue and reported continuing operating losses.
Financial results and liquidity
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 | Comparable 2018 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $8.6 million | $18.2 million | $12.2 million; $24.6 million |
| General and administrative expense | $3.6 million | $7.3 million | $3.4 million; $6.6 million |
| Total operating expenses | $12.2 million | $25.5 million | $15.6 million; $31.3 million |
| Net loss | $12.1 million | $25.2 million | $15.8 million; $31.7 million |
| Basic and diluted loss per share | $0.32 | $0.68 | $0.57; $1.15 |
Amounts are shown in 2019 and then 2018 order for the three- and six-month comparisons. With no revenue, profit margins are not applicable. The filing reports no product sales and expects continued operating losses.
- Cash and investments: At June 30, cash and cash equivalents were $37.2 million and marketable securities were $54.4 million, totaling $91.7 million. Restricted cash of $1.3 million was reported separately.
- Cash flow: Six-month operating cash use was $23.2 million, versus $26.6 million in 2018. Investing activities provided $14.2 million, largely reflecting marketable-security maturities and purchases. Financing activities used $1.7 million, including $1.8 million of loan repayments. Cash, cash equivalents, and restricted cash decreased by $10.8 million.
- Debt: Term-loan principal was $18.2 million, including $7.3 million current and $11.9 million long-term carrying value. The loan bears a variable rate of 1.25% above prime; the filing reports an effective annual rate of approximately 9.9%. Principal is scheduled through December 2021.
- Liquidity: Management expected cash, cash equivalents, and marketable securities to fund planned operations, capital expenditures, and debt requirements for at least 12 months from the filing’s issuance date. The loan includes minimum-liquidity requirements and restrictive covenants.
- Equity: Accumulated deficit was $376.2 million; stockholders’ equity was $72.1 million. The company had 37.3 million common shares outstanding at June 30.
Changes versus the prior comparable periods
- Second-quarter net loss narrowed by $3.6 million year over year; six-month net loss narrowed by $6.5 million.
- Research and development expense declined $3.6 million for the quarter and $6.4 million for the first half. Lower ZGN-1061 trial costs and reduced ZGN-1258 spending were major drivers; spending on ZGN-1345 increased as that program advanced.
- General and administrative expense rose $0.3 million for the quarter and $0.6 million for the first half, primarily due to personnel costs and stock-based compensation.
- Cash, cash equivalents, and marketable securities totaled $91.7 million, down from $118.1 million at December 31, 2018. The filing also reports a decrease in cash, cash equivalents, and restricted cash; movements between cash and marketable securities mean that measure differs from total available cash and investments.
Outlook, risks, and unusual items
- ZGN-1061: The FDA had imposed a full clinical hold on the U.S. IND in November 2018, citing possible cardiovascular safety risk based on an earlier compound. In July 2019, the company agreed with the FDA on an animal-study design intended to establish safety margins; topline results were expected by year-end 2019. The filing describes positive Phase 2 results outside the United States, but those results do not resolve the hold or establish future efficacy or safety.
- ZGN-1258: The company suspended plans to file an IND after an unexpected muscle-tissue finding in long-term rodent toxicology studies and was evaluating the finding. It reported the effect was not observed in other animal species in long-term models.
- ZGN-1345: This oral, liver-targeted candidate remained in nonclinical development; the company reported preliminary positive results in multiple liver-disease models and said further studies were ongoing.
- Restructuring after quarter-end: On July 24, 2019, the company announced an operating-expense reduction and workforce reduction of approximately 25%, in addition to other 2019 attrition. Related charges were not expected to be material.
- Financing and development risk: The company had never generated revenue, expected future losses, and stated it would need additional financing to support continuing operations and development. Funding may be unavailable or require dilution, restrictive debt terms, or licensing and collaboration arrangements.
- Other commitments: A new Boston headquarters lease had a 124-month initial term and $10.7 million of total payments over that term. The filing also disclosed up to $24.8 million in potential beloranib-related milestone payments, plus certain additional-product milestones and royalties if applicable; development using that licensed technology was no longer active.
Most important facts for investors to verify
- Confirm that this Zafgen 10-Q is the intended filing; the request names Larimar Therapeutics, Inc.
- Check the FDA’s clinical-hold status for ZGN-1061 and the results and implications of the planned animal study.
- Assess the ZGN-1258 toxicology finding and whether the program resumed, changed, or was discontinued.
- Reconcile the company’s cash runway with operating cash use, debt payments, liquidity covenants, and the post-quarter workforce reduction.
- Verify the effect of the July 2019 restructuring on spending, development priorities, and the stated runway.
- Review the term-loan covenant requirements and repayment schedule, and the obligations under the new headquarters lease.